James Tompkins, MD
Family Medicine · Byrdstown, TNNPI 1508057159
Payments from drug & device makers
Across 155 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$975
- Teva Pharmaceuticals USA, Inc.$461
- Lilly USA, LLC$202
- Novartis$199
- Amgen$127
- Melinta Therapeutics, LLC$51
- plus $746 from 27 others
What the payments were for
- Food & beverage$2,760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $975 |
| Teva Pharmaceuticals USA, Inc. | 22 | $461 |
| Lilly USA, LLC | 11 | $202 |
| Novartis | 11 | $199 |
| Amgen | 7 | $127 |
| Melinta Therapeutics, LLC | 2 | $51 |
| Abbott | 3 | $51 |
| Amarin Pharma, Inc. | 3 | $50 |
| Eisai Inc. | 3 | $48 |
| Alkermes, Inc. | 2 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 4 | $36 |
| Cumberland Pharmaceuticals, Inc. | 2 | $35 |
| Bayer | 2 | $32 |
| Merck | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Abiomed | 1 | $21 |
| Corcept Therapeutics | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| GSK | 1 | $15 |
| AbbVie | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Inari Medical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| DJO, LLC | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $9 |
How this compares
$2,760 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 295 | $348,739 |
| EliquisApixaban | 260 | $233,152 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 276 | $208,457 |
| OzempicSemaglutide | 174 | $188,653 |
| JardianceEmpagliflozin | 133 | $115,737 |
| XareltoRivaroxaban | 83 | $77,344 |
| AustedoDeutetrabenazine | 14 | $72,280 |
| TrulicityDulaglutide | 66 | $69,357 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 71 | $46,485 |
| Abilify MaintenaAripiprazole | 11 | $29,066 |
| LinzessLinaclotide | 40 | $27,754 |
| JanuviaSitagliptin Phosphate | 37 | $27,443 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $25,984 |
| EntrestoSacubitril/Valsartan | 29 | $24,536 |
| RybelsusSemaglutide | 26 | $24,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $202 | $418,097361 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $15 | $257,930377 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $975 | $228,093212 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat, Trijardy Xr, Tradjenta | $36 | $223,223276 claims |
| Johnson & JohnsonXarelto | $13 | $77,34483 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $461 | $72,28014 claims |
| MerckJanuvia, Lagevrio (Eua), Janumet | $25 | $42,23367 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $39 | $29,06611 claims |
| AbbVieLinzess | $15 | $27,75440 claims |
| NovartisEntresto | $199 | $24,53629 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $15 | $18,47230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Byrdstown
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.